All Posts Tagged With: "OGXI"
(ISIS) Isis Pharmaceuticals Reported Loss Widens
Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 20 cents per share in the first quarter of 2011, wider than the year-ago loss of 10 cents and the Zacks Consensus loss Estimate of 19 cents.
Revenues...
(TEVA) Teva Pharmaceuticals Industries Oncology Drug Progresses
Teva Pharmaceuticals Industries Ltd. (TEVA) and OncoGenex Pharmaceuticals, Inc. (OXGI) recently announced that they have initiated a second...
(TEVA) Teva Pharmaceutical Industries Expands Oncology Pipeline
In a move to expand its branded product pipeline, generic player Teva Pharmaceutical Industries Ltd. (TEVA) recently entered into a research and exclusive license agreement with Mersana Therapeutics for the...
(ISIS) Isis Pharmaceuticals’ Loss Widens
Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 16 cents per share in the fourth quarter, which was wider than the Zacks Consensus Estimate of a net loss of 11 cents. The company had reported a net...
(ISIS) Isis Pharmaceuticals Gains from Teva-OncoGenex Deal
Isis Pharmaceuticals, Inc. (ISIS) stands to benefit from the recently signed agreement between OncoGenex Pharmaceuticals (OGXI) and Teva...
(TEVA) Teva Pharmaceutical Expands Cancer Portfolio
In a move to expand its branded product offering, generic player Teva Pharmaceutical Industries Ltd. (TEVA) recently entered into a global license and collaboration agreement with OncoGenex Pharmaceuticals,...